Details der Publikation - Exoxaparin in hospitalized patients with moderate-severe COVID19

Exoxaparin in hospitalized patients with moderate-severe COVID19 : Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19 - INHIXACOVID19

Medienart:	Klinische Studie

Erscheinungsjahr:	2020
Erschienen:	2020

Enthalten in:	WHO International Clinical Trials Registry Platform - (2020) vom: 27. Juli Zur Gesamtaufnahme - year:2020

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: Hospitalized adult patients with microbiologically confirmed moderate-severe COVID-19 infection MedDRA version: 20.0Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestations MedDRA version: 20.0Level: SOCClassification code 10038738Term: Respiratory, thoracic and mediastinal disordersSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Phase: Phase 2 Recruitment Status: Authorised-recruitment may be ongoing or finished Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 24-06-2020, Last updated: 2022-11-24

ICTRP ID:	EUCTR2020-001308-40-IT INHIXACOVID19

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	CTG004711939

Internformat


LEADER	01000caa a22002652 4500
001	CTG004711939
003	DE-627
005	20230425175152.0
007	cr uuu---uuuuu
008	210507s2020 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)CTG004711939
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2020-001308-40-IT
035			\|a (UBBS_Klinische_Studien_WHO)INHIXACOVID19
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a Exoxaparin in hospitalized patients with moderate-severe COVID19 \|b Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19 - INHIXACOVID19
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 24-06-2020, Last updated: 2022-11-24
650		4	\|a Medical Condition: Hospitalized adult patients with microbiologically confirmed moderate-severe COVID-19 infection MedDRA version: 20.0Level: SOCClassification code 10021881Term: Infections and infestationsSystem Organ Class: 10021881 - Infections and infestations MedDRA version: 20.0Level: SOCClassification code 10038738Term: Respiratory, thoracic and mediastinal disordersSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 2
650		4	\|a Recruitment Status: Authorised-recruitment may be ongoing or finished
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2020) vom: 27. Juli
773	1	8	\|g year:2020 \|g day:27 \|g month:07
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001308-40 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|j 2020 \|b 27 \|c 07

Exoxaparin in hospitalized patients with moderate-severe COVID19 : Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19 - INHIXACOVID19

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände